Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
SPOTLIGHT: Deal or no deal for Lilly?
Remember the expert witness who leaked damaging documents about Zyprexa, Eli Lilly's schizophrenia med? He agreed to pay $100,000 to settle Lilly's lawsuit against him. But now the two are fighting over Lilly's' announcement of the deal because the company said he admitted breaking the law, but his lawyer says he admitted no such thing. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
